Clinical trials: Advanced Malignancy
Leukemia, Myelodysplastic Syndromes
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00002890
- Testing
- lintuzumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma
Research Study in Patients With Advanced Ovarian Epithelial Cancer
This research trial studies tissue samples from patients with ovarian cancer in the laboratory. Analyzing tissue samples from patients in the laboratory may help doctors learn more about cancer.
- Conditions
- Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer
- Trial name
- NCT00053235
- Testing
- Comparative Genomic Hybridization, Laboratory Biomarker Analysis, Polymerase Chain Reaction
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma…
- Trial name
- ANNOUNCE 2 (NCT02659020)
- Testing
- Olaratumab, Gemcitabine, Docetaxel
- Where
- 48 sites in United States, Australia and 8 more
- Volunteers
- 310 people
- Sponsor
- Eli Lilly and Company
Melanoma
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
The goal of this clinical research study is to learn if the combination of 2 drugs dabrafenib and trametinib can help to control melanoma that has or has not spread to the brain.
- Trial name
- NCT01619774
- Testing
- GSK2118436, GSK1120212
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Drug Resistance to Famitinib and Camrelizumab, Biomarkers for Efficacy and Toxicity
Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Trial name
- EBAOFC (NCT03919539)
- Testing
- 5hmc testing
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Multi-disciplinary Treatment
MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer
This is a prospective, multicenter, non-interventional, controlled clinical study. Evaluate MDT performance and benefit analysis in patients with advanced gastric or colorectal cancer after MDT discussion under real medical…
- Trial name
- NCT03400657
- Testing
- Multi-disciplinary Treatment
- Where
- China
- Volunteers
- 484 people
- Sponsor
- Peking University
Sarcoma, HER-2 Protein Overexpression
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this…
- Conditions
- Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma
- Trial name
- NCT04995003
- Testing
- T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Soft Tissue Sarcoma Adult, Advanced Cancer
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Patients with advanced soft tissue sarcoma(rhabdomyosarcoma and liposarcoma excluded), who experience progression after standard chemotherapy, have limited treatment options which promise a survival benefit.This trial tends to…
- Trial name
- NCT03104335
- Testing
- Apatinib
- Where
- 3 sites in China
- Sponsor
- Peking University People's Hospital
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer.
- Trial name
- NCT00047710
- Testing
- Bevacizumab, Capecitabine, Radiotherapy
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Ewing Sarcoma Family of Tumors
Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan
This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated…
- Trial name
- MGMTLiberati (NCT03542097)
- Testing
- MGMT methylation evaluation
- Where
- 5 sites in Italy, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Istituto Ortopedico Rizzoli
Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft…
- Conditions
- Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma
- Trial name
- NCT00720174
- Testing
- Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00096096
- Testing
- mycophenolate mofetil, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00004172
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Sponsor
- Northwestern University
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer.
- Trial name
- NCT00590902
- Testing
- OSI-774: erlotinib, TarcevaTM
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003637
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National Cancer Centre, Singapore
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003102
- Testing
- Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ludwig Institute for Cancer Research
Palliative Care, Wearable Electronic Devices
Wearable and Patient-reported Outcome-based Continuous Assessment and Support Alerts in Palliative Care
Non-professional carers (typically family members) play a critical role in providing adequate home care. This research explores the use of wearable sensors (WS) and electronic patient-reported outcome (ePRO) surveys to monitor…
- Conditions
- Palliative Care, Wearable Electronic Devices, Patient Reported Outcome Measures, Cancer
- Trial name
- wePRO-CASA (NCT05273580)
- Testing
- Garmin VivoSmart 4, mema - ilumivu
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Royal North Shore Hospital
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea
This study is designed to gather epidemiological data in Korea on HER2 incidence in gastric and gastroesophageal junction cancer as assessed by local laboratories in a real-life setting.
- Trial name
- NCT02538562
- Where
- 14 sites in South Korea
- Volunteers
- 1,695 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.